Advertisement

Die Wirkung von Aminorex (Menocil®) auf die Hämodynamik des kleinen und großen Kreislaufs bei i.v. Darreichung am Hund

  • O. Kraupp
  • W. Stühlinger
  • G. Raberger
  • K. Turnheim
Chapter

Schlüsselwörter

Aminorex Noradrenalin Pulmonaler Gefäßwiderstand Femoral-Gefäßwiderstand Rechtsventrikuläre Leistung 

Summary

The effects of a single i.v. injection or infusion of Aminorex (2-amino-5-phenyl-2-oxazoline-fumarate) on blood pressure, blood flow, and haemodynamic resistance of the pulmonary and femoral arteries were investigated in anaesthetized dogs and compared with those of Norepinephrine. The following results were obtained:
  1. 1.

    Aminorex (dose-range between 10 and 160 μg/kg i.v.) caused a transient increase in the mean blood pressure of the pulmonary artery and in the mean pulmonary perfusion pressure (P art. pulm. — P left atrium). At the same time the pulmonary blood flow fell by 10–20%. A dose-dependent increase in the vascular resistance of the pulmonary vessels was observed in all experiments. The effects lasted for 20 to 60 min, according to the dose. Isoproterenol (1, 0 αg/kg i.v.) led to a fall in the pulmonary vascular resistance and abolished the resistance increase following the Aminorex-administration.

     
  2. 2.

    An i.v. infusion of Aminorex (dose-range between 5 and 50 αg/kg/min) led to an increase in pulmonary blood pressure and vascular resistance. At the same time a slight decrease in heart rate and pulmonary blood flow was obtained. These pulmonary haemodynamic changes reached their maximum 15 min after the onset of the infusion and remained constant during the whole period of an infusion lasting 40 min. After discontinuing the infusion the pressure and resistance values returned only partially to the preinfusion values.

     
  3. 3.

    An infusion of 10 αg/kg/min Aminorex led to an increase in the blood pressure of the systemic circulation and in the total peripheral vascular resistance. Both changes were less marked when compared with the simultaneously occurring effects on the pulmonary haemodynamics. At the same time the blood flow in the femoral artery was diminished to a greater degree than in the pulmonary artery. As a result of the observed flow- and pressure changes in the pulmonary and femoral arteries the influence of an Aminorex-infusion on the haemodynamic resistance of both vessels was identical with regard to the time course and the intensity of the observed effects.

     
  4. 4.

    Pretreatment with Phentolamine abolished the effects of an infusion of 10 αg/kg/min Aminorex on pulmonary blood pressure and vascular resistance, whereas pretreatment with Propranolol enhanced these effects.

     
  5. 5.

    Following an i.v. infusion of 0.5 αg/kg/min Norepinephrine pulmonary blood pressure and vascular resistance rose only transiently, whereas the pulmonary blood flow decreased at the same time, due to an initial fall in heart rate. These initial changes did not last in spite of a continued Norepinephrine infusion.

     
  6. 6.

    The effects of Norepinephrine on the systemic blood pressure were more pronounced than those on the pulmonary blood pressure. As a consequence, the increase in the work done by the left ventricle was greater than the increase in the work done by the right ventricle. In contrast, the increase in blood pressure and vascular resistance caused by Aminorex was more pronounced in the pulmonary circulation and therefore the right ventricular work increased more than the left ventricular work.

     

Key-Words

Aminorex Norepinephrine Pulmonary Vascular Resistance Femoral Vascular Resistance Right Ventricular Work 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aviado, D.M.: The lung circulation. Oxford-Frankfurt: Pergamon Press 1965.Google Scholar
  2. Braun, G.A., G.I. Poos, and P.C. Johnson: Metabolism of aminorex. Fed. Proc. 24, 546b (1965).Google Scholar
  3. Günther, G., u. H. Schmidt: Über Befunde an Rattenorganen nach langdauernder Arterenolbehandlung. Z. Kreisl.-Forsch. 48, 127–135 (1959).Google Scholar
  4. Gurtner, H.P., M. Gertsch, C. Salzmann, M. Scherrer, P. Stucki u. F. Wyss: Häufen sich die primär vasculären Formen des chron. Cor pulmonale? Schweiz. med. Wschr. 98, 1579–1589, 1695-1707 (1968).Google Scholar
  5. Harmjanz, D., K. Gahl, H.S. Stender, H. Fabel, H. Deicher u. H. Schoen: Zur medikamentös induzierten pulmonalen Hypertonie. Dtsch. med. Wschr. 93, 2351 (1968)PubMedGoogle Scholar
  6. Howard, J.E., and W.H. Barker: Paroxysmal hypertension and other clinical manifestations associated with benign chromaffin cell tumors (Pheochromocytomata). Bull. Johns Hopk. Hosp. 61, 371–410 (1937).Google Scholar
  7. Kaindl, F., u. E. Kautek-Ogris: Symposion über prim. pulm. Hypertonie; Wien, 23. Nov. 1968. Z. Ges. inn. Med. (im Druck).Google Scholar
  8. Kraupp, O., G. Raberger u. W. Stühlinger: Symposion über prim. pulm. Hypertonie; Wien, 23. Nov. 1968. Z. Ges. inn. Med. (im Druck).Google Scholar
  9. Lang, E., E.J. Haupt, J.A. Köhler u. J. Schmidt: Cor pulmonale durch Appetitzügler? Münch. med. Wschr. 1969, 405-412.Google Scholar
  10. Lee, R.E.: Hemodynamic changes in the bulbar conjunctival capillary bed of subjects with hypertension associated with Cushing’s syndrome of Pheochromocytoma. Amer. J. Med. 19, 203–208 (1955).PubMedCrossRefGoogle Scholar
  11. Maier, H.C.: Intrathoracic pheochromocytoma with hypertension. Ann. Surg. 130, 1059–1065 (1949).PubMedCrossRefGoogle Scholar
  12. Minno, A.M., W.A. Bennett, and W.F. Kvale: Pheochromocytoma. New Engl. J. Med. 251, 959–964 (1954).PubMedCrossRefGoogle Scholar
  13. Paley, H.W., S.Y. Tsai, J.E. Johnson, Jr., W.C. Kennoyer, L.G. May, and E.G. Galveston: The effects of histamine and regitine on the pulmonary artery pressure in a case of Pheochromocytoma. J. Lab. clin. Med. 44, 905–906 (1954).Google Scholar
  14. Rivier, J.L.: Symposion über prim. pulm. Hypertonie; Wien, 23. Nov. 1968. Z. ges. inn. Med. (im Druck).Google Scholar
  15. Robinson, M.J., and A. Williams: Clinical and pathological details of two cases of pheochromocytoma in childhood. Arch. Dis. Childh. 31, 69–74 (1965).CrossRefGoogle Scholar
  16. Schwingshackl, H., H. Amor u. F. Dienstl: Primäre pulmonale Hypertonie bei sieben jüngeren Frauen. Dtsch. med. Wschr. 94, 639–645 (1969).PubMedCrossRefGoogle Scholar
  17. Sherwin, R.P.: Histopathology of pheochromocyioma. Cancer 12, 861–877 (1959).PubMedCrossRefGoogle Scholar
  18. Silva, T.F., and S.C. Sommers: Renal biopsy changes with Pheochromocytoma. Amer. J. med. Sci. 236, 700–704 (1958).PubMedCrossRefGoogle Scholar
  19. Sommers, S.C.: Pathology of the kidney and adrenal gland in relationship to hypertension: Hypertension. First Hahnemann symposion on hypertensive disease. Philadelphia-London: W.B. Saunders Comp. 1959.Google Scholar
  20. Wirz, P.: Symposion über prim. pulm. Hypertonie; Wien, 23. Nov. 1968. Z. ges. inn. Med. (im Druck).Google Scholar
  21. Withrington, P., and E. Zaimis: The reserpine-treated cat. Brit. J. Pharmacol. 17, 380–391 (1961).PubMedGoogle Scholar
  22. Yelnosky, J., R.J. Hewson, J. Mundy, and J. Mitchell: The cardiovascular effects of Aminorex, a new anorexigenic agent. Arch. int. Pharmacodyn. 164, 412–418 (1966).Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1969

Authors and Affiliations

  • O. Kraupp
    • 1
    • 2
  • W. Stühlinger
    • 1
  • G. Raberger
    • 1
  • K. Turnheim
    • 1
  1. 1.Institut für Pharmakologie und ToxikologieRuhr-Universität BochumDeutschland
  2. 2.Pharmakologisches InstitutRuhr-Universität BochumWienÖsterrich

Personalised recommendations